tion of mixed wild-type and mutant p53 molecules conmice metastasized with high frequency. Correspondverts wild-type p53 into the mutant conformation in vitro ingly, the embryonic fibroblasts from the p53 515A/515A (Milner et al., 1991) . Gain-of-function mutations, on the mutant mice displayed enhanced cell proliferation, other hand, are those missense mutations in which mu-DNA synthesis, and transformation potential. The distant p53 has additional functions not seen in wild-type ruption of p63 and p73 in p53 Ϫ/Ϫ cells increased transp53. For example, the p53R175H mutant, when overexformation capacity and reinitiated DNA synthesis to pressed in a nontransformed cell line lacking p53, yields levels observed in p53 515A/515A cells. Additionally, p63 tumors in nude mice, while the parental cell line does and p73 were functionally inactivated in p53 515A cells.
not (Dittmer et al., 1993). Transgenic mice overexpressThese results provide in vivo validation for the gain-of-
ing the human p53R175H mutation in epithelial cells function properties of certain p53 missense mutations exhibit an increased susceptibility to chemical carcinoand suggest a mechanistic basis for these phenogenesis with shorter latency of tumor development as types.
compared to mice lacking p53 (Li et al., 1998; Wang et al., 1998a Wang et al., , 1998b ).
Introduction
While these experiments suggest both dominant-negative and gain-of-function phenotypes of p53 mutants, The p53 tumor suppressor encodes a transcriptional they do not mimic the occurrence of p53 mutations in regulator that controls cell cycle progression and apohuman tumors, since strong promoters drive expression ptosis. In response to DNA damage or cellular stress, of the mutant p53 transgene to very high levels. The p53 activity increases, initiating a cascade of events best experiments that assay these functions of p53 are that block cell division. Thus, the p53 gene itself or the ones in which mutant p53 is not vastly overproduced. p53 pathway is derailed in the development of most if Some of these experiments have been performed in not all cancers. Somatic inactivation of p53 occurs in tissue culture using retroviral vectors to express wildover 50% of human tumors, the majority of which are type and/or mutant p53 in cells lacking endogenous p53 missense mutations in the DNA binding domain (Bartek mutation with gain-of-function properties, p53R273H, Inherited mutations in the p53 tumor suppressor occur yielded cells that are smaller, have a higher saturation in individuals with Li-Fraumeni syndrome (LFS), a syndensity, and form colonies in soft agar as compared to drome characterized by a predisposition to tumor develcells infected with a single copy of the wild-type p53 retrovirus. However, and perhaps more importantly, a cell line containing one copy of each of the wild-type cell line that expresses wild-type p53 alone. These data Results indicate that, in the heterozygous state, wild-type p53 is dominant over mutant p53. These data contrast with Generation of p53 515A Knockin Mice To establish a LFS mouse model with a specific p53 studies in murine ES cells in which the equivalent mutation was introduced into the p53 locus. Upon exposure missense mutation, we generated mice with a targeted mutation at the endogenous p53 locus using the creto ␥ radiation, heterozygous ES cells show a dominantnegative phenotype (de Vries et al., 2002) . These opposloxP system ( Figure 1A) . We engineered an arg-to-his substitution at amino acid 172 that corresponds to the ing results suggest that, under different conditions, the same p53 mutation can or cannot function as a dominant hot spot mutation at arg 175 in humans. Southern blot analysis was used to verify proper targeting of the ennegative. Importantly, these in vitro experiments cannot determine the effect of mutant p53 on survival and tumor dogenous p53 allele ( Figure 1B) and p53 Ϫ/515A mice were identical, perhaps owing to the Thus, the interdependency of p63, p73, and p53 sugrapid nature of tumor development (Figure 2A) . The surgests that disruption of any of these components cripvival curves of p53 ϩ/515A and p53 ϩ/Ϫ mice also overlapped ples p53 tumor suppression function. The ability of muand showed no statistical difference ( Figure 2B ). No tant p53 to bind and inhibit the function of p63 and p73 differences between survival of male and female mice suggests that mutant p53 would be more detrimental were observed (data not shown). Our survival data for than absence of p53. p53 ϩ/Ϫ and p53 Ϫ/Ϫ mice were consistent with previously To more accurately simulate the Li-Fraumeni synpublished data (Harvey et al., 1993a; Jacks et al., 1994). drome and to examine the mechanistic nature of misThe most common tumor types seen in mice with any sense mutations on tumorigenesis in vivo, we generated of the above genotypes were lymphomas and sarcomas and characterized a mouse model with an arg-to-his ( properties that allow metastasis. Mouse embryonic fimice. Thus, in a C57BL/6 background, the comparison of broblasts (MEFs) from mice with one or two copies of p53 mutant (p53
515A
) and null alleles showed no differthe p53 515A allele showed increased growth rates and ences in the kinds of tumors that these mice developed. higher saturation densities. Moreover, these cells conHowever, the tumor spectrum of heterozygous mice tinued to undergo DNA synthesis under conditions in showed one marked difference. The osteosarcomas and which p53 heterozygous and null cells did not. Mechacarcinomas in p53 ϩ/515A mice metastasized (Table 1 and nistically, p53R172H bound p63 and p73 in mouse tumor Figure 2C ). Tumors and metastases from p53 ϩ/515A mice cell lines and downmodulation of p63 and p73 in p53 expressed high levels of p53 ( Figure 2C) and have significant implications for therapy. mice developed osteosarcomas and carcinomas that tive, then mice null for mdm2 and p53 ϩ/515A should be born. Crosses between mdm2 ϩ/Ϫ and mdm2
metastasized at high frequency. Since the p53R172H mutant was not very stable in mice were performed. If the missense mutant has a dominant-negative activity in this context, then we exp53 ϩ/515A MEFs (see Figure 1C ) but the equivalent mutant is stable in human tumors, we performed immunohistopected 50% of the newborn mice to be mdm2
. This population of mice was not observed in ten offchemical analysis on some of the p53 ϩ/515A mouse tumors. The results consistently showed stable p53 in spring born (data not shown), suggesting that the wildtype p53 allele in p53 ϩ/515A mice remained functional tumor cells but not adjacent normal tissue ( Figure 2C ), suggesting that other factors contribute to mutant p53 during embryogenesis. To examine p53-dependent apoptosis in response to DNA damage, embryos at 13.5 stability. One possible explanation for the increased levels of p53 in tumors is the loss of the wild-type p53 allele. days gestation were irradiated and assayed for apoptosis in the region of the developing hypothalamus (Figure We therefore examined tumors for loss of heterozygosity (LOH) by SSCP (single-stranded conformation polymor-2E). In this assay, p53 null mice showed no evidence of apoptosis, while p53 ϩ/Ϫ mice showed a high number of phism) analysis using DNA isolated from tumors and normal tissues in p53 ϩ/515A mice by in situ laser capture apoptotic cells, although not quite as high as p53 ϩ/ϩ mice. Under the same conditions, p53 ϩ/515A mice showed as we have previously described ( Figure 2D ) (Liu et al., 2000) . Only three of 13 tumors analyzed showed LOH, almost a complete absence of apoptosis, suggesting that, in response to DNA damage, the p53R172H mutant suggesting that loss of the wild-type p53 allele is not a prerequisite for increased mutant p53 levels. exerts a dominant-negative effect. These data and published in vitro data suggest that, in response to DNA damage, the mutant p53 can inhibit the function of wild- The p53 515A/515A and p53 ϩ/515A MEFs initially did not show pected, and grew even faster than p53 Ϫ/Ϫ cells. By day 4, all cell lines reached saturation, but the p53 515A/515A and any significant differences in growth rate compared to the p53 Ϫ/Ϫ cell lines, but differences became apparent p53 ϩ/515A MEFs reached a much higher saturation density compared to any of other genotypes. These data sugat day 4 ( Figure 3A) . The p53 515A/515A and p53 ϩ/515A MEFs grew more rapidly than p53 ϩ/Ϫ and p53 ϩ/ϩ cells, as exgest that the p53 515A mutation gives MEFs a growth ad- 515A/515A mutant backor HA-tagged p73␣ expression plasmids, with a p21 ground also appeared larger. These findings support a promoter luciferase plasmid, and with control or p53 role for the p53 515A allele in cooperation with activated specific siRNAs. In all cases, samples with p53 siRNA ras in transformation of cells, further supporting a gainshowed increased p21 promoter activity as compared of-function hypothesis for the p53R172H mutant.
to samples with control siRNA ( Figure 4C ). Both p63 and p73 were able to activate the p21 promoter to a greater extent in the absence of mutant p53. Experiments using Gain of Function via p63 and p73 Several mechanisms have been proposed to account both p63␣ and p73␣ (at half the DNA concentration each) also showed increased p21 promoter activity upon inhifor the gain-of-function effect observed for p53 mutants. Ϫ/Ϫ and p53 515A/515A MEFs in cooperation with activated ras was measured using a focus-forming assay. Low-passage MEFs were infected with a retroviral vector containing an activated Ha-ras V12 cDNA or vector control and diluted with nontransfected cells before plating. Foci were counted after 14 days of growth. bition of mutant p53. Even the addition of p53 siRNA tein levels by immunohistochemisty ( Figure 5A ) and Western blot analyses ( Figure 5B ), while the levels of alone showed a slight increase in p21 luciferase activity ( Figure 4C ). We also measured the ability of endogenous p63 and p73 remained high with control siRNAs. To examine if the siRNAs specific for p63 and p73 p63 and p73 to activate the endogenous p21 promoter. In transfection experiments using 318-1 cells, the addicould inhibit p63 and p73 expression in MEFs, we performed Western blot ( Figure 5C ) and real-time RT-PCR tion of p53 siRNA inhibited the levels of endogenous p53 and increased p21 mRNAs, as measured by realanalyses ( Figure 5D ). The data clearly show reduction of p63 and p73 protein levels. At the mRNA level, p63 and time RT-PCR ( Figure 4D ). These data indicate functional inactivation of p63 and p73 by the p53R172H mutant p73 mRNAs were barely detectable when the respective siRNAs were used. Thus, the p63 and p73 siRNA dramatprotein.
To determine the role of p63 and p73 in transformaically reduced the levels of endogenous mRNAs and proteins in MEFs. tion, we downmodulated expression of p63 and p73 in focus-forming assays with MEFs of different genotypes.
Next, focus-forming assays were performed utilizing these p63 and p73 siRNAs. MEFs were infected with First, to check the specificity of siRNAs, FLAG-tagged p63␣ and myc-tagged p73␣ expression constructs were activated ras, followed by transfection with siRNAs for p63 and p73, or control siRNA. Control transfection excotransfected with control siRNAs and siRNAs specific for p63 or p73 into H1299 cells. The p63 and p73 siRNAs periments with or without siRNA showed no significant effect on the number of foci that formed in p53 Ϫ/Ϫ and showed almost complete inhibition of p63 and p73 pro- 
MEFs and in p53
515A/515A MEFs transfected with control p73 resulted in continued DNA synthesis beyond day 6, similar to p53 515A/515A MEFs ( Figures 6C and 6D) . These siRNAs. In addition, p53 515A/515A MEFs showed no noticeable difference in foci number when transfected with findings provided further evidence that the p63 and/or p73 pathways are inhibited in p53 515A/515A MEFs. both p63 and p73 siRNAs, suggesting the increased number of foci is caused by the inhibition of p63 and/ or p73 in p53 515A/515A MEFs. Discussion
In this study, we have generated a knockin allele of a Inhibition of p63 and p73 in p53 Ϫ/Ϫ MEFs Reinitiates DNA Synthesis common p53 mutation in a more faithful reproduction of the LFS. Several important observations arose from To examine the importance of p63 and p73 in the gainof-function phenotype, we exploited another difference these studies. First, the osteosarcomas and carcinomas from p53 ϩ/515A mice metastasize, as in humans, to the between mutant and wild-type cells. Cells with one or two copies of the p53 null allele cease to replicate DNA lymph nodes, lung, liver, and brain, while tumors from p53 ϩ/Ϫ mice do not (Donehower et al., 1992; Jacks et after short-term culture (Figure 3B ), while cells with one or two copies of the p53 515A allele reinitiate DNA syntheal., 1994). These data are supported by a metastatic phenotype seen in tumors from mice with a hypomorsis. We therefore transfected siRNAs for p63 and p73, or control siRNA into low passage MEFs, and monitored phic allele of the same mutation ( ity on wild-type and mutant p53 function. Importantly, the p53R172H protein in p53 ϩ/515A mice is not stable but but do not exclude the possibility that other factors might also contribute. To correlate the tissue culture becomes stable in tumors. In the developing embryo, the absence of mdm2 resulted in a lethal phenotype in data with tumorigenesis in vivo, we showed the interaction of endogenous p63 and p73 proteins with mutant p53 ϩ/515A mice, suggesting that wild-type p53 is functional. Since the mdm2 null phenotype is rescued by p53 in three independent tumor cell lines derived from p53 ϩ/515A mice that had lost the wild-type p53 allele. loss of p53, the lack of dominant-negative activity of p53R172H in embryogenesis is clear. The inability of the Moreover, functional inactivation of p63 and p73 was observed in the same tumor cell lines. Our data indicate mutant p53 to function in the presence of a wild-type allele suggests that p53R172H cannot inactivate p63 that mutant tumor cell lines producing p53R172H from a single copy of the gene lack functional p63 and p73. and p73 in embryogenesis and is supported by the absence of lethal phenotypes, as seen with loss of p63 However, while we have observed the interaction of p63 and p73 with mutant p53 and have identified a role of and p73 (Yang et al., 1999 (Yang et al., , 2000 p73, a possibility that is supported by the observation that p63 or p73 null embryos also lack a p53-dependent apy. Clearly, typing of p53 mutations should be performed in human tumors to determine the relevance of our mouse models to human disease.
Transfections and Luciferase Assay
For transfection experiments, lipofectamine reagent was used according to the manufacturer's protocol (Invitrogen). DNA and siRNAs Experimental Procedures were mixed in a 5:1 (g) ratio. For Western blotting and immunostaining, cells were harvested 24-42 hr after transfection. For DNA synGeneration of p53 515A Knockin Mice The targeting vector was generated by cloning a loxP-flanked thesis and focus-forming assays, cells were used 48 hr after transfection. For luciferase assays, cells were seeded at 70% confluency PGKneo cassette into the second AccI site of intron 4 of a p53 genomic fragment. An arginine-to-histidine substitution (CGC to 1 day before transfection. The p21 reporter plasmid (pGLp21Luc) (0.7 g) was used with an internal control, 0.15 g of pRL-TK (Pro-CAC) at codon 172 was performed by site-directed mutagenesis. The resulting construct was then cloned into a vector containing a mega). Either p63␣ or p73␣ expressing plasmids (0.3 g) were cotransfected with these luciferase plasmids. When both p63 and p73 thymidine kinase (TK) cassette. The entire targeting construct was sequence verified (data not shown) and linearized with NotI. Tarwere cotransfected, 0.15 g of each plasmid was used. In addition, 2 l of 20 M control siRNA (Scramble II, Dharmacon) or p53-specific geting vector (25 g) was electroporated into AB-1 embryonic stem (ES) cells. DNA from G418-resistant FIAU-sensitive ES colonies was siRNA was also added to the transfection. The dual reporter luciferase assay system (Promega) was used to measure p21 promoter subjected to Southern blot analysis. Two targeted ES cell clones were injected into C57BL/6 blastocysts and transferred into pseudoactivity according to manufacturer's instruction.
